Show Summary Details
Page of

Biochemical markers of bone metabolism in CKD 

Biochemical markers of bone metabolism in CKD
Biochemical markers of bone metabolism in CKD

Pablo Ureña

, Klaus Olgaard

, and Kevin Martin

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 07 August 2020

In the absence of bone biopsy, there is no ideal marker of bone remodeling in CKD patients. Recent studies have shown that PTH alone is not necessarily a good biomarker for bone turnover in the setting of CKD, particularly when the levels are modestly increased (3–9 times the upper limit of normal). As such, increased plasma PTH levels are not always synonymous of high turnover bone disease and vice versa. Other bone biomarkers discussed in this chapter provide useful information at the extremes but each one alone is not more valuable that PTH, particularly at distinguishing low from normal bone turnover. The combined use of PTH with some of the more accessible biomarkers of bone remodeling have the potential to improve the diagnosis, monitoring, and treatment monitoring of CKD-MBD in the future. However, further studies are clearly required to examine the utility of these biomarkers and their correlations with bone histology in the current era.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.